Correction to: Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: A randomised clinical trial.
The graphical abstract (available at https://doi.org/10.1007/s00125-023-06053-9) included a typographical error (‘insulin-dependent insulin secretion’, rather than ‘glucose-dependent insulin secretion’). The online version has been corrected. (Figure presented.).